LJUBLJANA (Slovenia), August 12 (SeeNews) - Slovenian pharmaceutical products wholesaler Salus [LJE:SALR] said its consolidated net profit declined to 6.4 million euro ($6.6 million) in the first half of 2022 from 7.4 million euro in the same period of last year.
Consolidated net sales revenue went up by an annual 13.7% to 247.4 million euro in the six-month period through June 2022, Salus said in a filing with the Ljubljana Stock Exchange on Thursday.
The company's operating profit decreased to 8.1 million euro from 9.3 million euro in January-June 2021, while EBITDA totalled 10.2 million euro, down from 10.5 million euro in the like period of last year.
Ljubljana-based Salus is one of Slovenia's leading wholesalers of pharmaceutical and medical products.
($ = 0.96701 euro)